American Heart Journal
Volume 150, Issue 2 , Pages 215-220 , August 2005

Left ventricular ejection fraction to predict early mortality in patients with non–ST-segment elevation acute coronary syndromes

  • Xavier Bosch, MD

      Affiliations

    • Institut de Malalties Cardiovasculars, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Spain, Barcelona, Spain
    • ,
  • Pierre Théroux, MD

      Affiliations

    • Research Center, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Pierre Théroux, MD, Research Center, Montreal Heart Institute, University of Montreal, 5000 Belanger East, Montreal, Quebec, Canada H1T 1C8.

Received 31 October 2003 ,Accepted 20 September 2004.

References 

  1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation. 2002;106:1893–1900
  2. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without ST-segment elevation. The Task Force of the European Society of Cardiology. Eur Heart J. 2002;23:1809–1840
  3. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation. 2000;101:2557–2567
  4. Antman EM, Cohen M, Bernink PJL, et al. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision-making. JAMA. 2000;284:835–842
  5. Sabatine MS, Januzzi JL, Snapinn S, et al. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol. 2001;88:488–492
  6. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
  7. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23:223–229
  8. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622–1626
  9. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation. 1994;90:2645–2657
  10. Brezinski D, Stone PH, Muller JE, et al. Prognostic significance of the Karnofsky performance status score in patients with acute myocardial infarction: comparison with the left ventricular ejection fraction and the exercise treadmill test performance. The MILIS study group. Am Heart J. 1991;121:1374–1381
  11. Volpi A, De Vita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: results of the GISSI-2 data base. The ad hoc working group of the Gruppo Iyaliano per lo Studio della Sopravivenza nell'Infarto Miocardico (GISSI)-2 data base. Circulation. 1993;88:416–429
  12. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497
  13. Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410–414
  14. Harrell F, Lee KL. Regression modeling strategies for improved prognostic prediction. Stat Med. 1984;3:143–152
  15. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events study group. N Engl J Med. 1997;337:447–452
  16. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601
  17. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436–443
  18. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1899–1900
  19. FRagmin, and Fast Revascularization during Instability in Coronary Artery Disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–715
  20. Hoekstra JW, Pollack CV, Roe MT, et al. Improving the care of patients with non–ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med. 2002;9:1146–1155
  21. Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1177–1189
  22. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002;23:1190–1201
  23. Bosch X, López de Sá E, López Sendón J, et al. Clinical characteristics, prognosis, and variability in the management of non–ST-segment elevation acute coronary syndromes. Data from the PEPA registry. Rev Esp Cardiol. 2003;56:346–353
  24. Luchi RJ, Scott SM, Deupree RH. Principal investigators and their associates of Veterans Administration Cooperative Study No. 28: comparison of medical and surgical treatment for unstable angina pectoris. N Engl J Med. 1987;316:977–984
  25. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000;343:915–922
  26. Rioufol G, Finet G, André-Fouet X, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804–808
  27. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021
  28. James SK, Lindahl B, Siegbahn A, et al. N-Terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275–281

PII: S0002-8703(04)00659-3

doi: 10.1016/j.ahj.2004.09.027

American Heart Journal
Volume 150, Issue 2 , Pages 215-220 , August 2005

Article Tools

* Image Usage & Resolution